Будь ласка, використовуйте цей ідентифікатор, щоб цитувати або посилатися на цей матеріал: http://ir.librarynmu.com/handle/123456789/5764
Повний запис метаданих
Поле DCЗначенняМова
dc.contributor.authorKordubailo, L.-
dc.contributor.authorNikitin, O.-
dc.contributor.authorNishkumay, O.-
dc.contributor.authorSamchuk, P.-
dc.date.accessioned2023-02-07T08:53:58Z-
dc.date.available2023-02-07T08:53:58Z-
dc.date.issued2021-
dc.identifier.issn1996-353X-
dc.identifier.issn2311-6951-
dc.identifier.urihttp://ir.librarynmu.com/handle/123456789/5764-
dc.description.abstractAbstract: the prevalence of kidney stone disease (KSD) and osteoporosis (OP) increases every year. In the prevention of osteoporosis, it is important to consume a suffcient amount of calcium-rich foods in the daily diet, as well as the use of calcium. One of the important reasons for the insuffcient use of calcium-containing products and medicines is the anxiety not only of patients, but, very importantly, of doctors as much as possible. This has serious justifcation, as nephrolithiasis occurs in approximately 5% of the population, and the risk of developing kidney stones during life is 8-10%. It is believed that secondary hyperparathyroidism, which is caused by hypocalcemia due to insuffcient consumption of calcium-containing products and impaired renal function, leads to increased bone resorption, formation of kidney stone disease. It is important to consider that against the background of hypertensive, atherosclerotic kidney disease, tubulo-interstitial lesions of the kidneys with decreasing glomerular fltration rate decreases the synthesis of 1α-hydroxylase - an enzyme by which 25-hydroxycholecalciferol (25 (OH) active D3, calcium) form of vitamin D3–1.25 dihydroxycholecalciferol (1.25 (OH) 2D3, calcitriol - D-hormone) and secondary hyperparathyroidism develops. In this case, the purpose of correction along with the treatment of urolithiasis (spa treatment, given the attendance of the presence of KSD, to carry out the distance lithotripsy), intake of active metabolites of vitamin D (should be started with low doses, independent of the initial PTH concentration, and then titrated based on the PTH response) conducting X-ray densitometry.uk_UA
dc.language.isoenuk_UA
dc.publisherUkrainian Scientifc Medical Youth Journaluk_UA
dc.subjecturolithiasis, osteoporosis, hyperparathyroidism, calcitrioluk_UA
dc.titleKidney stone disease and osteoporosos - topic issues of comorbidityuk_UA
dc.typeArticleuk_UA
Розташовується у зібраннях:Наукові публікації кафедри урології

Файли цього матеріалу:
Файл Опис РозмірФормат 
Kidney stone disease and osteoporosos - topic issues of comorbidity.pdf414,11 kBAdobe PDFПереглянути/Відкрити


Усі матеріали в архіві електронних ресурсів захищені авторським правом, всі права збережені.